Werewolf Therapeutics Receives Nasdaq Delisting Notice for Sub-$1.00 Stock Price
HOWL sits 17% above its 52-week low of $0.53 on light trading volume (0.3× avg).
Summary
Werewolf Therapeutics, Inc. received a Nasdaq deficiency letter for failing to meet the minimum $1.00 bid price requirement, initiating a 180-day period to regain compliance and avoid potential delisting.
Key Events · Corporate Governance and Compliance · HOWL
-
Nasdaq Deficiency Notice Received
The company received a notice from Nasdaq on February 4, 2026, indicating non-compliance with the minimum $1.00 bid price rule, as its common stock traded below this threshold for 30 consecutive business days.
-
180-Day Compliance Period
Werewolf Therapeutics has an initial 180 calendar days, until August 3, 2026, to regain compliance by having its stock close at or above $1.00 for at least 10 consecutive business days.
-
Potential for Further Extension
If compliance is not met within the initial period, the company may be eligible for an additional 180-day period if it transfers its listing to the Nasdaq Capital Market and meets other listing standards.
-
Delisting Risk
There is no assurance that the company will be able to regain compliance with the bid price requirement or avoid eventual delisting, which could severely impact its market access and investor appeal.
Analysis · HOWL · Life Sciences
Werewolf Therapeutics, Inc. has received a deficiency letter from Nasdaq for failing to maintain a minimum bid price of $1.00 per share. This notice, while not an immediate delisting, signals significant financial distress and a lack of investor confidence, especially following recent substantial share sales by a major investor, MPM BioVentures, as reported in January. The company now faces a critical 180-day period to regain compliance, which may require a reverse stock split or other measures to boost its share price. Failure to do so could lead to delisting, severely impacting its ability to raise capital and maintain liquidity, further complicating its already challenging financial position.
At the time of this filing, HOWL was trading at $0.62 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $29.7M. The 52-week trading range was $0.53 to $2.38. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.